Adalimumab biosimilar (Celltrion)

阿达木单抗生物类似药 (Celltrion)

Report date: 2026/03/30 20:02:02

Base Information

Drug NameAdalimumab biosimilar (Celltrion)
Drug Alias NameAdalimumabum (Celltrion)阿达利木单抗 (Celltrion)阿达姆单抗 (Celltrion)Adalimumab (Celltrion)adalimumab-aaty +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisPediatric ulcerative colitisPsoriasis +[13] 
Global Approved IndicationsPlaque psoriasisPediatric ulcerative colitisPsoriasis +[13] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2021/02/11
Country/TerritoryUnited StatesPolandSouth Korea +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCelltrion Inc
China Registration ClassN/A

Develop Information

Active CompaniesCelltrion Healthcare Hungary KftCelltrion IncRani Therapeutics Holdings Inc +[4] 
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPediatric ulcerative colitisPsoriasis +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB04
Related LinksN/A